MEDBOX | Toolbox Vaccine Candidates & Research

TOOLBOX

Advanced search

Create your MEDBOX

TOOLBOX

Advanced search

Create your MEDBOX

LIST OPTIONS

FILTER BY LANGUAGE

FILTER BY COUNTRY

SORT BY

RESULTS/PAGE

LIST TYPE

132 records

	Recomendaciones provisionales para el uso de la vacuna BBV152 COVAXIN® de Bharat Biotech contra la COVID-19: orientaciones provisionales, primera publicación: 3 de noviembre de 2021, actualización: 15 Organización Mundial de la Salud OMS (2022) C_WHO View PDF(20) Download (7) Add to my MEDBOX Tags: COVID-19, Vaccination, Covaxin, Source: https://apps.who.int/iris/bitstream/hand
	Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine World Health Organization WHO (2022) C_WHO View PDF(35) Download (28) Add to my MEDBOX 6 June 2022 These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. This document has been updated: Version 6 June 2022 Tags: vaccine, johnson&Johnson, recommendations, approval, COVID-19, SARS-CoV-2, vector-basierter Impfstoff, Source: https://apps.who.int/iris/rest/bitstream
	Предварительные рекомендации по применению инактивированной вакцины CoronaVac против COVID-19, разработанной Sinovac World Health Organization WHO (2022) C_WHO View PDF(29) Download (23) Add to my MEDBOX Временное руководство (‎Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г. Tags: vaccine, COVID-19, sinovac, Source: https://apps.who.int/iris/bitstream/hand
	WHO’s Science in 5 Episode #70 - Upcoming new vaccines World Health Organization WHO (2022) C_WHO Open external link (326) Add to my MEDBOX 29 April 2022 What are the new vaccines in the pipeline? What are the challenges to turning vaccines into vaccination ? What timelines can we expect for future vaccines? WHO’s Dr Katherine O’Brien explains in Science in 5 Tags: Vaccination, Immunization, research, pipeline, COVID-19, general public, Video, Source: https://youtu.be/h8CVs3yYXwA
	Recomendaciones provisionales para el uso de la vacuna inactivada contra la COVID-19 CoronaVac, desarrollada por Sinovac World Health Organization WHO (2022) C_WHO View PDF(36) Download (22) Add to my MEDBOX orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022 Tags: Immunization, vaccine, COVID-19, SARS-CoV-2, sinovac, Source: https://apps.who.int/iris/bitstream/hand
	Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (Arabic), updated March 2022 World Health Organization WHO (2022) C_WHO View PDF(23) Download (11) Add to my MEDBOX Tags: sinopharm, vaccine, COVID-19, SARS-CoV-2, vaccine candidates, inactivated vaccines, Source: https://apps.who.int/iris/bitstream/hand
	Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 inactivé BIBP développé par China National Biotec Group (‎CNBG)‎, Sinopharm , mise à jour le 15 mars 2022 Organisation Mondiale de la Santé OMS (2022) C_WHO View PDF(31) Download (30) Add to my MEDBOX Tags: COVID-19, Vaccines, guidance, global, vaccine candidates, SARS-CoV-2, sinopharm, Source: https://apps.who.int/iris/bitstream/hand
	Vaccines/COVID-19 vaccine EUL issued World Health Organization WHO (2022) C_WHO Open external link (311) Add to my MEDBOX This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize the efficiency of assessment, review and authorizations of medical products. Vaccines are undoubtedly the most complex medical products to develop, from concept to a stage where sufficient evidence of quality, safety and efficacy are collected to provide an assurance that their use will provide more benefits than risks when used in the context of a public health emergency Tags: vaccine candidates, COVID-19, recommendations, submission, quality data, Emergency Use Authorization, emergency use, Source: https://extranet.who.int/pqweb/vaccines/
	Coronavirus Vaccine Tracker Zimmer, C, J. Corum and S. Wee New York Times (2022) CC Open external link (871) Add to my MEDBOX Tags: vaccine, research, COVID-19, approval, development, Source: https://www.nytimes.com/interactive/2020
	Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Vygen-Bonnet S, Koch J, Bogdan C, et al. (2022) C1 View PDF(92) Download (66) Add to my MEDBOX Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfempfehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, pediatrics, Children, Adolescents, booster, Source: https://www.rki.de/DE/Content/Infekt/Epi

132 records

132 records